NCT03660631

Brief Summary

The objective of this study is to evaluate the implementation of of a remote, pharmacist-led cardiovascular risk service (CVRS) in 12 large, organizationally and culturally diverse hospitals and health-systems, many with high proportions of minority and underserved patients.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
542

participants targeted

Target at P75+ for not_applicable hypertension

Timeline
Completed

Started Sep 2018

Longer than P75 for not_applicable hypertension

Geographic Reach
1 country

14 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 20, 2018

Completed
17 days until next milestone

First Posted

Study publicly available on registry

September 6, 2018

Completed
21 days until next milestone

Study Start

First participant enrolled

September 27, 2018

Completed
4.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2023

Completed
1.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2024

Completed
Last Updated

August 13, 2024

Status Verified

August 1, 2024

Enrollment Period

4.8 years

First QC Date

August 20, 2018

Last Update Submit

August 12, 2024

Conditions

Outcome Measures

Primary Outcomes (2)

  • Factors influencing intervention implementation fidelity

    Themes will be identified through interviews with key individuals involved in implementation of study intervention. Data from interviews will be analyzed using ATLAS ti to determine frequency and density of themes identified in interviews.

    12 months following the start of the intervention at each site

  • Effect of physician/pharmacist collaboration on implementation fidelity

    Development of implementation fidelity measures and adherence to fidelity measures

    12 months following the start of the intervention at each site

Secondary Outcomes (4)

  • Adherence to guidelines for primary and secondary prevention of cardiovascular disease

    12 months after the start of the intervention for each subject

  • Reach and adoption of intervention

    12 months following the start of the intervention at each site

  • Development of payment contracts

    36 months following the start of recruitment

  • Development of payment contracts

    36 months following the start of recruitment

Study Arms (2)

CVRS Early Intervention

EXPERIMENTAL

Patients participating in intervention offices will receive the pharmacist-led CVRS intervention for 12 months.

Behavioral: CVRS Intervention

CVRS Delayed Intervention

OTHER

Patients participating in control site offices will not have any contact with the CVRS pharmacist for the first 12 months of their participation in the study. They will receive the study intervention during months 13-24.

Behavioral: CVRS Intervention

Interventions

1. Evaluate gaps in therapy 2. Contact patients regularly by email, phone and/or text message 3. Assess and counsel for medication adherence, side effects, life-style behaviors 4. Develop an action plan and send recommendations to provider

CVRS Delayed InterventionCVRS Early Intervention

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient Subjects:
  • English or Spanish speaking
  • Seen in the clinic at least once in the previous 12 months
  • Currently has one of the following diseases:
  • Diabetes with HA1c 9.0% or greater and/or
  • Hypertension (uncomplicated) with systolic blood pressure 150 mm Hg or greater

You may not qualify if:

  • Inability to give consent
  • Nursing home residence
  • No telephone
  • Cancer with a life expectancy less than 24 months
  • Pregnancy
  • Diagnosis of dementia
  • Plans to terminate care from the clinic within 24 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (14)

Idaho State University

Pocatello, Idaho, 83201, United States

Location

University of Illinois at Chicago: Mile Square Health Center

Chicago, Illinois, 60608, United States

Location

Carle Foundation Hospital

Mahomet, Illinois, 61853, United States

Location

Carle Foundation Hospital

Rantoul, Illinois, 61866, United States

Location

Genesis Family Medical Center

Davenport, Iowa, 52804, United States

Location

University of Iowa

Iowa City, Iowa, 52242, United States

Location

UIHC River Crossing

Riverside, Iowa, 52327, United States

Location

Siouxland Family Medicine Center

Sioux City, Iowa, 51104, United States

Location

Northeast Iowa Family Practice Center

Waterloo, Iowa, 50702, United States

Location

Henry Ford Health System: Harbortown

Detroit, Michigan, 48207, United States

Location

University of North Carolina

Chapel Hill, North Carolina, 27514, United States

Location

Temple University

Philadelphia, Pennsylvania, 19140, United States

Location

Texas Tech University Health Science Center

Amarillo, Texas, 79106, United States

Location

Community Health Center of Snohomish County

Everett, Washington, 98203, United States

Location

Related Publications (1)

  • Kennelty KA, Engblom NJ, Carter BL, Hollingworth L, Levy BT, Finkelstein RJ, Parker CP, Xu Y, Jackson KL, Dawson JD, Dorsey KK. Dissemination of a telehealth cardiovascular risk service: The CVRS live protocol. Contemp Clin Trials. 2021 Mar;102:106282. doi: 10.1016/j.cct.2021.106282. Epub 2021 Jan 12.

MeSH Terms

Conditions

HypertensionDiabetes Mellitus

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular DiseasesGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

  • Korey Kennelty, PharmD

    University of Iowa

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: Patient subjects will participate in their office's randomization group (intervention or control) for the 1st 12 months of their participation. After 12 months, each patient subject in the control group will receive the study intervention for months 13-24. Patient subjects in the intervention will be followed by study pharmacists during months 13-24.
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

August 20, 2018

First Posted

September 6, 2018

Study Start

September 27, 2018

Primary Completion

June 30, 2023

Study Completion

December 30, 2024

Last Updated

August 13, 2024

Record last verified: 2024-08

Data Sharing

IPD Sharing
Will share

1. Provide de-identified SAS datasets in transport format with the protocol, data dictionaries user manual . A data sharing agreement will be required. 2. Share data with all participating sites and place study links and information on PBRN website136 3. Present results to other PBRNs through AHRQ meetings. 4. Post the development and results on the .213 PRagmatic-Explanatory Continuum Indicator Summary

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
Time Frame
12 months following the start of the study intervention.

Locations